A panelist discusses how the ARANOTE phase 3 trial investigated darolutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, providing an overview of ...

A panelist discusses how ARANOTE contributes to the evidence for treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), comparing it with other trials like ARCHES, TITAN, ...

John Michael DiBianco, MD, discusses findings from the BLUES trial. A recent study evaluated silicone vs polyurethane stents found that the primary outcome of pain intensity and interference at 7 to ...

The relationship between clinical trial results and real-world experience with enzalutamide and darolutamide shows important patterns: The alignment between trial data and clinical experience supports ...

A panelist discusses how they would communicate these comparative study results to patients by explaining that both enzalutamide and darolutamide effectively control metastatic prostate cancer when ...

Amy E. Krambeck, MD, recaps her talk from AUA 2025. She began by highlighting the wealth of options for benign prostatic hyperplasia (BPH), emphasizing the need for clinicians to be strategic in their ...

Investigators found that benefits of treatments that are observed in trials also appear in the real world. A recent study examined the relationship between randomized controlled trials and real-world ...

Paul E. Dato, MD, discusses how when selecting abiraterone for metastatic hormone-sensitive prostate cancer patients, there are 3 formulations to consider: standard, generic, and micronized versions, ...

Initial ADT reduced PSA from 78 to 17 ng/mL and improved pain score from 6/10 to 3/10 Abiraterone acetate (1000 mg daily with 5 mg prednisone twice a day) further suppressed PSA to 9 ng/mL Patient ...

Durvalumab plus BCG therapy significantly improved DFS in high-risk NMIBC compared to BCG alone, with no detriment in overall survival. The phase 3 POTOMAC trial involved 1018 patients across 12 ...

Panelists discuss how specific tumor characteristics, such as papillary architecture and presence of carcinoma in situ, guide risk-adapted treatment decisions in non–muscle-invasive bladder cancer.

The AUSCO trial showed a 94% success rate in achieving significant continence improvement in men with SUI using the artificial urinary sphincter. The study found no device infections and low ...